Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity
Abstract Context Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development. Objective To evaluate the hepatic and s...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2024-06, Vol.109 (7), p.1781-1792 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1792 |
|---|---|
| container_issue | 7 |
| container_start_page | 1781 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 109 |
| creator | Núñez-Sánchez, María Ángeles Martínez-Sánchez, María Antonia Martínez-Montoro, José Ignacio Balaguer-Román, Andrés Murcia-García, Elena Fernández-Ruiz, Virginia Esperanza Ferrer-Gómez, Mercedes Martínez-Cáceres, Carlos Manuel Sledzinski, Tomasz Frutos, María Dolores Hernández-Morante, Juan José Fernández-García, José Carlos Queipo-Ortuño, María Isabel Ruiz-Alcaraz, Antonio José Mika, Adriana Ramos-Molina, Bruno |
| description | Abstract
Context
Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development.
Objective
To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors.
Methods
This was a case–control study in patients with obesity undergoing bariatric surgery at a university hospital between January 2020 and December 2021. Participants were distributed in 3 groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction–associated steatohepatitis (n = 32). Hepatic and serum FA levels were determined by gas chromatography-mass spectrometry. Nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by reverse transcription quantitative polymerase chain reaction.
Results
The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared with those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD, being significantly different between the 3 groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD.
Conclusion
Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver. |
| doi_str_mv | 10.1210/clinem/dgae028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2929032986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/clinem/dgae028</oup_id><sourcerecordid>3164512138</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-34708ac17389de6412a84a3b42109e225f07190821133ac01599d8ba3b65a2983</originalsourceid><addsrcrecordid>eNqFkUtLxDAUhYMoOo5uXUrAjS6qefSVZfENlRkcRXclTe9opG1qkwrz783Q0YUbV5fL_e6Bcw5CR5ScU0bJhap1C81F9SaBsHQLTagIoyChItlGE0IYDUTCXvfQvrUfhNAwjPgu2uMpo0kaiwn6zHWnK9NohbNW1iurLX6EL5C1xVntoJdOm9Zi3eI76Pyi8E2G571Z6hpwZq1RWjqo8It27_ghW-RXeOHkG6w_5p6H1tnxOCvBarc6QDtLrw6HmzlFzzfXT5d3QT67vb_M8kDxKHEBDxOSSkUTnooK4pAymYaSl6F3LYCxaEm8S-KNUM6lIjQSokpLT8SRZCLlU3Q66na9-RzAuqLRVkFdyxbMYAsmmCDck7FHT_6gH2bofRy24DQOI580Xwuej5TqjbU9LIuu143sVwUlxbqMYiyj2JThH443skPZQPWL_6TvgbMRMEP3n9g3K96TUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3164512138</pqid></control><display><type>article</type><title>Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Núñez-Sánchez, María Ángeles ; Martínez-Sánchez, María Antonia ; Martínez-Montoro, José Ignacio ; Balaguer-Román, Andrés ; Murcia-García, Elena ; Fernández-Ruiz, Virginia Esperanza ; Ferrer-Gómez, Mercedes ; Martínez-Cáceres, Carlos Manuel ; Sledzinski, Tomasz ; Frutos, María Dolores ; Hernández-Morante, Juan José ; Fernández-García, José Carlos ; Queipo-Ortuño, María Isabel ; Ruiz-Alcaraz, Antonio José ; Mika, Adriana ; Ramos-Molina, Bruno</creator><creatorcontrib>Núñez-Sánchez, María Ángeles ; Martínez-Sánchez, María Antonia ; Martínez-Montoro, José Ignacio ; Balaguer-Román, Andrés ; Murcia-García, Elena ; Fernández-Ruiz, Virginia Esperanza ; Ferrer-Gómez, Mercedes ; Martínez-Cáceres, Carlos Manuel ; Sledzinski, Tomasz ; Frutos, María Dolores ; Hernández-Morante, Juan José ; Fernández-García, José Carlos ; Queipo-Ortuño, María Isabel ; Ruiz-Alcaraz, Antonio José ; Mika, Adriana ; Ramos-Molina, Bruno</creatorcontrib><description>Abstract
Context
Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development.
Objective
To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors.
Methods
This was a case–control study in patients with obesity undergoing bariatric surgery at a university hospital between January 2020 and December 2021. Participants were distributed in 3 groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction–associated steatohepatitis (n = 32). Hepatic and serum FA levels were determined by gas chromatography-mass spectrometry. Nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by reverse transcription quantitative polymerase chain reaction.
Results
The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared with those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD, being significantly different between the 3 groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD.
Conclusion
Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgae028</identifier><identifier>PMID: 38217869</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adult ; Bariatric Surgery ; Case-Control Studies ; Dietary intake ; Fatty Acids - metabolism ; Fatty Liver - metabolism ; Fatty Liver - pathology ; Female ; Food chains ; Gas chromatography ; Gastrointestinal surgery ; Gene frequency ; Hepatocytes ; High fat diet ; Humans ; Lipid Metabolism ; Lipidomics ; Lipogenesis ; Liver - metabolism ; Liver - pathology ; Liver diseases ; Male ; Mass spectroscopy ; Metabolism ; Middle Aged ; Nutritional status ; Obesity ; Obesity - complications ; Obesity - metabolism ; Patients ; Reverse transcription ; Risk factors</subject><ispartof>The journal of clinical endocrinology and metabolism, 2024-06, Vol.109 (7), p.1781-1792</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-34708ac17389de6412a84a3b42109e225f07190821133ac01599d8ba3b65a2983</citedby><cites>FETCH-LOGICAL-c357t-34708ac17389de6412a84a3b42109e225f07190821133ac01599d8ba3b65a2983</cites><orcidid>0000-0003-2877-5652 ; 0000-0001-6804-5449</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38217869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Núñez-Sánchez, María Ángeles</creatorcontrib><creatorcontrib>Martínez-Sánchez, María Antonia</creatorcontrib><creatorcontrib>Martínez-Montoro, José Ignacio</creatorcontrib><creatorcontrib>Balaguer-Román, Andrés</creatorcontrib><creatorcontrib>Murcia-García, Elena</creatorcontrib><creatorcontrib>Fernández-Ruiz, Virginia Esperanza</creatorcontrib><creatorcontrib>Ferrer-Gómez, Mercedes</creatorcontrib><creatorcontrib>Martínez-Cáceres, Carlos Manuel</creatorcontrib><creatorcontrib>Sledzinski, Tomasz</creatorcontrib><creatorcontrib>Frutos, María Dolores</creatorcontrib><creatorcontrib>Hernández-Morante, Juan José</creatorcontrib><creatorcontrib>Fernández-García, José Carlos</creatorcontrib><creatorcontrib>Queipo-Ortuño, María Isabel</creatorcontrib><creatorcontrib>Ruiz-Alcaraz, Antonio José</creatorcontrib><creatorcontrib>Mika, Adriana</creatorcontrib><creatorcontrib>Ramos-Molina, Bruno</creatorcontrib><title>Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Abstract
Context
Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development.
Objective
To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors.
Methods
This was a case–control study in patients with obesity undergoing bariatric surgery at a university hospital between January 2020 and December 2021. Participants were distributed in 3 groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction–associated steatohepatitis (n = 32). Hepatic and serum FA levels were determined by gas chromatography-mass spectrometry. Nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by reverse transcription quantitative polymerase chain reaction.
Results
The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared with those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD, being significantly different between the 3 groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD.
Conclusion
Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver.</description><subject>Adult</subject><subject>Bariatric Surgery</subject><subject>Case-Control Studies</subject><subject>Dietary intake</subject><subject>Fatty Acids - metabolism</subject><subject>Fatty Liver - metabolism</subject><subject>Fatty Liver - pathology</subject><subject>Female</subject><subject>Food chains</subject><subject>Gas chromatography</subject><subject>Gastrointestinal surgery</subject><subject>Gene frequency</subject><subject>Hepatocytes</subject><subject>High fat diet</subject><subject>Humans</subject><subject>Lipid Metabolism</subject><subject>Lipidomics</subject><subject>Lipogenesis</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Mass spectroscopy</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Nutritional status</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - metabolism</subject><subject>Patients</subject><subject>Reverse transcription</subject><subject>Risk factors</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtLxDAUhYMoOo5uXUrAjS6qefSVZfENlRkcRXclTe9opG1qkwrz783Q0YUbV5fL_e6Bcw5CR5ScU0bJhap1C81F9SaBsHQLTagIoyChItlGE0IYDUTCXvfQvrUfhNAwjPgu2uMpo0kaiwn6zHWnK9NohbNW1iurLX6EL5C1xVntoJdOm9Zi3eI76Pyi8E2G571Z6hpwZq1RWjqo8It27_ghW-RXeOHkG6w_5p6H1tnxOCvBarc6QDtLrw6HmzlFzzfXT5d3QT67vb_M8kDxKHEBDxOSSkUTnooK4pAymYaSl6F3LYCxaEm8S-KNUM6lIjQSokpLT8SRZCLlU3Q66na9-RzAuqLRVkFdyxbMYAsmmCDck7FHT_6gH2bofRy24DQOI580Xwuej5TqjbU9LIuu143sVwUlxbqMYiyj2JThH443skPZQPWL_6TvgbMRMEP3n9g3K96TUw</recordid><startdate>20240617</startdate><enddate>20240617</enddate><creator>Núñez-Sánchez, María Ángeles</creator><creator>Martínez-Sánchez, María Antonia</creator><creator>Martínez-Montoro, José Ignacio</creator><creator>Balaguer-Román, Andrés</creator><creator>Murcia-García, Elena</creator><creator>Fernández-Ruiz, Virginia Esperanza</creator><creator>Ferrer-Gómez, Mercedes</creator><creator>Martínez-Cáceres, Carlos Manuel</creator><creator>Sledzinski, Tomasz</creator><creator>Frutos, María Dolores</creator><creator>Hernández-Morante, Juan José</creator><creator>Fernández-García, José Carlos</creator><creator>Queipo-Ortuño, María Isabel</creator><creator>Ruiz-Alcaraz, Antonio José</creator><creator>Mika, Adriana</creator><creator>Ramos-Molina, Bruno</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2877-5652</orcidid><orcidid>https://orcid.org/0000-0001-6804-5449</orcidid></search><sort><creationdate>20240617</creationdate><title>Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity</title><author>Núñez-Sánchez, María Ángeles ; Martínez-Sánchez, María Antonia ; Martínez-Montoro, José Ignacio ; Balaguer-Román, Andrés ; Murcia-García, Elena ; Fernández-Ruiz, Virginia Esperanza ; Ferrer-Gómez, Mercedes ; Martínez-Cáceres, Carlos Manuel ; Sledzinski, Tomasz ; Frutos, María Dolores ; Hernández-Morante, Juan José ; Fernández-García, José Carlos ; Queipo-Ortuño, María Isabel ; Ruiz-Alcaraz, Antonio José ; Mika, Adriana ; Ramos-Molina, Bruno</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-34708ac17389de6412a84a3b42109e225f07190821133ac01599d8ba3b65a2983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Bariatric Surgery</topic><topic>Case-Control Studies</topic><topic>Dietary intake</topic><topic>Fatty Acids - metabolism</topic><topic>Fatty Liver - metabolism</topic><topic>Fatty Liver - pathology</topic><topic>Female</topic><topic>Food chains</topic><topic>Gas chromatography</topic><topic>Gastrointestinal surgery</topic><topic>Gene frequency</topic><topic>Hepatocytes</topic><topic>High fat diet</topic><topic>Humans</topic><topic>Lipid Metabolism</topic><topic>Lipidomics</topic><topic>Lipogenesis</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Mass spectroscopy</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Nutritional status</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - metabolism</topic><topic>Patients</topic><topic>Reverse transcription</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Núñez-Sánchez, María Ángeles</creatorcontrib><creatorcontrib>Martínez-Sánchez, María Antonia</creatorcontrib><creatorcontrib>Martínez-Montoro, José Ignacio</creatorcontrib><creatorcontrib>Balaguer-Román, Andrés</creatorcontrib><creatorcontrib>Murcia-García, Elena</creatorcontrib><creatorcontrib>Fernández-Ruiz, Virginia Esperanza</creatorcontrib><creatorcontrib>Ferrer-Gómez, Mercedes</creatorcontrib><creatorcontrib>Martínez-Cáceres, Carlos Manuel</creatorcontrib><creatorcontrib>Sledzinski, Tomasz</creatorcontrib><creatorcontrib>Frutos, María Dolores</creatorcontrib><creatorcontrib>Hernández-Morante, Juan José</creatorcontrib><creatorcontrib>Fernández-García, José Carlos</creatorcontrib><creatorcontrib>Queipo-Ortuño, María Isabel</creatorcontrib><creatorcontrib>Ruiz-Alcaraz, Antonio José</creatorcontrib><creatorcontrib>Mika, Adriana</creatorcontrib><creatorcontrib>Ramos-Molina, Bruno</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Núñez-Sánchez, María Ángeles</au><au>Martínez-Sánchez, María Antonia</au><au>Martínez-Montoro, José Ignacio</au><au>Balaguer-Román, Andrés</au><au>Murcia-García, Elena</au><au>Fernández-Ruiz, Virginia Esperanza</au><au>Ferrer-Gómez, Mercedes</au><au>Martínez-Cáceres, Carlos Manuel</au><au>Sledzinski, Tomasz</au><au>Frutos, María Dolores</au><au>Hernández-Morante, Juan José</au><au>Fernández-García, José Carlos</au><au>Queipo-Ortuño, María Isabel</au><au>Ruiz-Alcaraz, Antonio José</au><au>Mika, Adriana</au><au>Ramos-Molina, Bruno</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2024-06-17</date><risdate>2024</risdate><volume>109</volume><issue>7</issue><spage>1781</spage><epage>1792</epage><pages>1781-1792</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Abstract
Context
Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development.
Objective
To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors.
Methods
This was a case–control study in patients with obesity undergoing bariatric surgery at a university hospital between January 2020 and December 2021. Participants were distributed in 3 groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction–associated steatohepatitis (n = 32). Hepatic and serum FA levels were determined by gas chromatography-mass spectrometry. Nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by reverse transcription quantitative polymerase chain reaction.
Results
The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared with those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD, being significantly different between the 3 groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD.
Conclusion
Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>38217869</pmid><doi>10.1210/clinem/dgae028</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2877-5652</orcidid><orcidid>https://orcid.org/0000-0001-6804-5449</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2024-06, Vol.109 (7), p.1781-1792 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2929032986 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adult Bariatric Surgery Case-Control Studies Dietary intake Fatty Acids - metabolism Fatty Liver - metabolism Fatty Liver - pathology Female Food chains Gas chromatography Gastrointestinal surgery Gene frequency Hepatocytes High fat diet Humans Lipid Metabolism Lipidomics Lipogenesis Liver - metabolism Liver - pathology Liver diseases Male Mass spectroscopy Metabolism Middle Aged Nutritional status Obesity Obesity - complications Obesity - metabolism Patients Reverse transcription Risk factors |
| title | Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T05%3A05%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipidomic%20Analysis%20Reveals%20Alterations%20in%20Hepatic%20FA%20Profile%20Associated%20With%20MASLD%20Stage%20in%20Patients%20With%20Obesity&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=N%C3%BA%C3%B1ez-S%C3%A1nchez,%20Mar%C3%ADa%20%C3%81ngeles&rft.date=2024-06-17&rft.volume=109&rft.issue=7&rft.spage=1781&rft.epage=1792&rft.pages=1781-1792&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgae028&rft_dat=%3Cproquest_cross%3E3164512138%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3164512138&rft_id=info:pmid/38217869&rft_oup_id=10.1210/clinem/dgae028&rfr_iscdi=true |